|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600123205 |
|
最近更新日期: Date of Last Refreshed on: |
2026-04-22 16:45:51 |
|
注册时间: Date of Registration: |
2026-04-22 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
评估妊娠期高血糖患者应用持续动态血糖监测系统进行自我血糖监测准确性的自身配对临床研究 |
|
Public title: |
Self-paired clinical study on the accuracy of continuous glucose monitoring system for self-monitoring of blood glucose in patients with gestational hyperglycemia |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
评估妊娠期高血糖患者应用持续动态血糖监测系统进行自我血糖监测准确性的自身配对临床研究 |
|
Scientific title: |
Self-paired clinical study on the accuracy of continuous glucose monitoring system for self-monitoring of blood glucose in patients with gestational hyperglycemia |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
陈英 |
研究负责人: |
花晓琳 |
|
Applicant: |
Chen Ying |
Study leader: |
Hua Xiaolin |
|
申请注册联系人电话: Applicant telephone: |
+86 135 6475 4082 |
研究负责人电话:
Study leader's |
+86 189 3050 2621 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
cy13564754082@163.com |
研究负责人电子邮件: Study leader's E-mail: |
huaxiaolin_sh@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国上海市奉贤区金钱公路1567号 |
研究负责人通讯地址: |
中国上海市徐汇区华山路1961号 |
|
Applicant address: |
1567 Jin Qian Highway, Fengxian District, Shanghai, China |
Study leader's address: |
1961 Huashan Road, Xuhui District, Shanghai, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中国福利会国际和平妇幼保健院 |
||
|
Applicant's institution: |
International Peace Maternity & Child Health Hospital of the China Welfare Institute |
||
|
研究负责人所在单位: |
中国福利会国际和平妇幼保健院 |
||
|
Affiliation of the Leader: |
International Peace Maternity & Child Health Hospital of the China Welfare Institute |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
GKLW-A-2026-001-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国福利会国际和平妇幼保健院 |
||
|
Name of the ethic committee: |
International Peace Maternity & Child Health Hospital of the China Welfare Institute |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-01-14 00:00:00 | ||
|
伦理委员会联系人: |
张延菲 |
||
|
Contact Name of the ethic committee: |
Zhang Yanfei |
||
|
伦理委员会联系地址: |
中国上海市徐汇区华山路1961号 |
||
|
Contact Address of the ethic committee: |
1961 Huashan Road, Xuhui District, Shanghai, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 6407 0434 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
中国福利会国际和平妇幼保健院 |
||||||||||||||||||||||
|
Primary sponsor: |
International Peace Maternity & Child Health Hospital of the China Welfare Institute |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国上海市徐汇区华山路1961号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
1961 Huashan Road, Xuhui District, Shanghai, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-funded |
||||||||||||||||||||||
|
研究疾病: |
妊娠期高血糖 |
||||||||||||||||||||||
|
Target disease: |
Gestational Hyperglycemia |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
本研究计划纳入在本中心建卡并进行产前检查,确诊为妊娠期高血糖且自愿或者自行使用CGMS进行血糖监测的患者。研究将对比CGMS监测结果与产前检查时的静脉血糖检测结果,以评估CGMS的准确性和安全性。 1. 研究的主要目的 (1) 通过妊娠期高血糖患者静脉血糖检测与同一时刻CGMS所测血糖数值自身配对比较,确定其自行应用的CGMS监测血糖的准确性、有效性,确保患者母胎安全、避免不良事件发生。 2. 研究的次要目的 (1) 通过该研究了解应用CGMS的妊娠期高血糖孕妇母胎结局(如巨大儿、难产、产后出血等母体并发症发生率;新生儿Apgar评分、出生体重、新生儿肺炎、入住NICU率等新生儿并发症的发生率)。 (2) 若患者出现TAR尤其是TBR临床表现时CGMS提醒的准确性,以疾病不良事件(如低血糖、高血糖漏报)发生率作为安全性评价指标,评价CGMS在临床实践中的安全性。 (3) 该临床研究评估结果有助于为妊娠期高血糖患者应用CGMS进行自我血糖监测提供临床应用、推荐和推广的依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study plans to include patients who have registered at our center for prenatal care, are diagnosed with gestational hyperglycemia, and voluntarily or independently use CGMS for blood glucose monitoring. The study will compare CGMS monitoring results with venous blood glucose test results during prenatal check-ups to evaluate the accuracy and safety of CGMS. 1. Primary objectives of the study (1) By comparing paired venous blood glucose test results with CGMS-measured blood glucose values at the same time points in patients with gestational hyperglycemia, the study aims to determine the accuracy and effectiveness of self-applied CGMS for blood glucose monitoring, ensuring maternal and fetal safety and preventing adverse events. 2. Secondary objectives of the study (1) Through this study, to understand the maternal and fetal outcomes (e.g., incidence of macrosomia, dystocia, postpartum hemorrhage, and other maternal complications; neonatal Apgar scores, birth weight, neonatal pneumonia, NICU admission rates, and other neonatal complications) in pregnant women with gestational hyperglycemia using CGMS. (2) To assess the accuracy of CGMS alerts when patients exhibit clinical manifestations of TAR, especially TBR, using the incidence of adverse events (e.g., hypoglycemia, missed hyperglycemia reports) as safety evaluation indicators, thereby evaluating the safety of CGMS in clinical practice. (3) The results of this clinical study will provide a basis for the clinical application, recommendation, and promotion of CGMS for self-blood glucose monitoring in patients with gestational hyperglycemia. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1. 本中心建卡产前检查; 2. 确诊为妊娠期高血糖(如PGDM或者GDM)患者; 3. 自行选择应用CGMS监测血糖的患者(针对T1DM患者研究者可推荐其应用CGMS,但针对T2DM或者GDM患者则不做推荐,但不限制其自行应用,患者选择CGMS品牌研究者不做推荐和限制); 4. 年龄在 18 岁及以上; 5. 具有一定的文字阅读能力; 6. 自愿入组并签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Prenatal examinations with registration at this center; 2. Patients diagnosed with gestational hyperglycemia (such as PGDM or GDM); 3. Patients who voluntarily choose to use CGMS for blood glucose monitoring (for T1DM patients, researchers may recommend CGMS use, but for T2DM or GDM patients, it is not recommended, though self-application is not restricted; researchers neither recommend nor restrict the choice of CGMS brand); 4. Aged 18 years or older; 5. Possess basic literacy skills; 6. Willing to participate and sign the informed consent form. |
||||||||||||||||||||||
|
排除标准: |
1. 严重精神障碍(如抑郁症或焦虑症); 2. 伴有癫痫或认知障碍; 3. 研究者认为不宜参加本临床研究的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Severe mental disorders (such as depression or anxiety); 2. Accompanied by epilepsy or cognitive impairment; 3. Patients deemed by investigators unsuitable for participation in this clinical study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-01-14 00:00:00至 To 2026-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-01-28 00:00:00 至 To 2026-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究结束后半年;国家生物信息中心(https://www.cncb.ac.cn/) |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Six months after the completion of the research; China National Center for Bioinformation (https://www.cncb.ac.cn/) |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
电子采集和管理系统(Electronic Data Capture, EDC) |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Electronic Data Capture, EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |